Drug Development for Rare Diseases
1st Edition
Published on 13. February 2023
232 pages
978-1-000-82022-5 (ISBN)
Description
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed
to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence
inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.
Key Features:
* Rare disease.
* Drug development.
* Innovative clinical trial design.
* Regulatory approval.
* Real-world evidence.
to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence
inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.
Key Features:
* Rare disease.
* Drug development.
* Innovative clinical trial design.
* Regulatory approval.
* Real-world evidence.
More details
Series
Edition
1. Auflage
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Illustrations
1 Tables, color; 22 Tables, black and white; 5 Line drawings, color; 2 Line drawings, black and white; 5 Illustrations, color; 2 Illustrations, black and white
ISBN-13
978-1-000-82022-5 (9781000820225)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Bo Yang | Yang Song | Yijie Zhou
Drug Development for Rare Diseases
Book
02/2023
1st Edition
Chapman & Hall/CRC
€186.10
Shipment within 15-20 days
Persons
Bo Yang is the Vice President, Biometrics and Real World Evidence at Vertex Pharmaceuticals, USA.
Yang Song is the Executive Director, Biostatistics Group Head of Pipeline Development at Vertex Pharmaceuticals, USA.
Yijie Zhou is the Executive Director, Real World Statistics and Analytics at Vertex Pharmaceuticals, USA.
Yang Song is the Executive Director, Biostatistics Group Head of Pipeline Development at Vertex Pharmaceuticals, USA.
Yijie Zhou is the Executive Director, Real World Statistics and Analytics at Vertex Pharmaceuticals, USA.
Content
1. Introduction to Rare Disease Therapy Development 2. Challenges and Opportunities in Rare Disease Drug 3. Developing Drugs for Rare Diseases: Regulatory Strategies 4. Clinical Trial Design and Analysis Considerations for Rare Diseases 5. Use of Real-World Evidence to Support Drug Development 6. Clinical Development of Pediatric Program within Rare Diseases 7. Use of Modeling and Simulation in Support of Drug Development for Rare Diseases 8. Case Studies of Rare Disease Drug Development
